Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

FIALA Ondrej FINEK Jindrich POPRACH Alexandr MELICHAR Bohuslav KOPECKY Jindrich ZEMANOVA Milada KOPECKOVA Katerina MLCOCH Tomas DOLEŽAL Tomáš CAPKOVA Lenka BUCHLER Tomas

Year of publication 2020
Type Article in Periodical
Magazine / Source Cancers
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/
Doi http://dx.doi.org/10.3390/cancers12040808
Keywords renal cell carcinoma; Memorial Sloan-Kettering Cancer Center risk; sunitinib; first line; outcome
Description Background: The Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.